Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model

Angiology

Volumn 62, Issue 2, 2011, Pages 144-154

  Paraskevas, Kosmas I ^a,b   Pantopoulou, Alkistis ^a   Vlachos, Ioannis S ^a   Agrogiannis, George ^a   Iliopoulos, Dimitrios G ^a   Karatzas, Gabriel ^a   Tzivras, Dimitrios ^a   Mikhailidis, Dimitri P ^c   Perrea, Despina N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

dyslipidemia; ezetimibe; fibrates; metabolic syndrome; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; C57BL 6 MOUSE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EXPERIMENT; FOOD; LIPID DIET; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN;

ANIMALS; AZETIDINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FENOFIBRATE; HEPTANOIC ACIDS; HYPOLIPIDEMIC AGENTS; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; PYRROLES;

EID: 78651398376     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710387919     Document Type: Article

References (50)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421.
2. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology. 2004 ; 55 (6). 589-612.
3. Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP Definitions of metabolic syndrome: where are we now ? Curr Vasc Pharmacol. 2006 ; 4 (3). 185-197.
4. Miyaki A., Maeda S., Yoshizawa M., et al. Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology. 2009 ; 60 (3). 351-357.
5. Stone NJ, Schmeltz LR Metabolic syndrome management. Expert Opin Pharmacother. 2007 ; 8 (13). 2059-2075.
6. Chen J., Townsend RR Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. Expert Opin Pharmacother. 2007 ; 8 (13). 2001-2009.
7. Ginsberg HN, Stalenhoef AF The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk. 2003 ; 10 (2). 121-128.
8. Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B., Mitchell YB Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 ; 25 (6). 1670-1686.
9. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW ; STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005 ; 95 (3). 360-366.
10. Stender S., Schuster H., Barter P., Watkins C., Kallend D. ; MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005 ; 7 (4). 430-438.
11. Stalenhoef AF, Ballantyne CM, Sarti C., et al. A comparative study with rosuvastatin is subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 ; 26 (24). 2664-2672.
12. Rizzo M., Berneis K. The clinical significance of the size of low- density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin. 2007 ; 23 (5). 1103-1111.
13. Tsimihodimos V., Miltiadous G., Daskalopoulou SS, Mikhailidis DP, Elisaf MS Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol. 2005 ; 3 (1). 87-98.
14. Davidson MH, Bays HE, Stein E., Maki KC, Shalwitz RA, Doyle R. ; Trims Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 ; 29 (6). 268-273.
15. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low-density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin. 2005 ; 21 (6). 959-969.
16. Kalogirou M., Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007 ; 23 (5). 1169-1176.
17. Yamaoka-Tojo M., Tojo T., Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol. 2008 ; 6 (4). 271-281.
18. Papanas N., Maltezos E., Mikhailidis DP Metformin: diamonds are forever. Expert Opin Pharmacother. 2009 ; 10 (15). 2395-2397.
19. Nambi V., Ballantyne CM Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006 ; 98 (4A). 34i - 38i.
20. Davidson MH Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 ; 5 (1). 145-156.
21. Murdock DK, Jansen D., Juza RM, et al. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. WMJ. 2006 ; 105 (5). 22-25.
22. Paraskevas KI, Karatzas G., Pantopoulou A., Iliopoulos DG, Perrea D. Targeting dyslipidemia in the metabolic syndrome: an update. Curr Vasc Pharmacol. 2010 ; 8 (4). 450-463.
23. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997 ; 38 (1). 41-48.
24. Ness GC, Holland RC, Lopez D. Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption. Exp Biol Med (Maywood). 2006 ; 231 (5). 559-565.
25. Hennuyer N., Tailleux A., Torpier G., et al. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2005 ; 25 (9). 1897-1902.
26. Nachtigal P., Pospisilova N., Jamborova G., et al. Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol. 2007 ; 85 (8). 767-773.
27. Momi S., Impagnatiello F., Guzzetta M., et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol. 2007 ; 570 (1-3). 115-124.
28. Guclu F., Ozmen B., Hekimsoy Z., Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother. 2004 ; 58 (10). 614-618.
29. Huptas S., Geiss HC, Otto C., Parhofer KG Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol. 2006 ; 98 (1). 66-69.
30. Nash DT Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. J Natl Med Assoc. 2005 ; 97 (12). 1600-1607.
31. Efstratiadis G., Tsiaousis G., Athyros VG, et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology. 2006 ; 57 (3). 303-311.
32. Paraskevas KI, Bessias N., Perdikides TP, Mikhailidis DP Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin. 2009 ; 25 (7). 1807-1809.
33. Rysz J., Aronow WS, Stolarek RS, Hannam S., Mikhailidis DP, Banach M. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets. 2009 ; 13 (5). 541-550.
34. Paraskevas KI, Stathopoulos V., Mikhailidis DP Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008 ; 6 (4). 237-239.
35. Iso H., Sato S., Kitamura A., et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke. 2007 ; 38 (6). 1744-1751.
36. McNeill AM, Katz R., Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study. J Am Geriatr Soc. 2006 ; 54 (9). 1317-1324.
37. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs. 2001 ; 1 (5). 327-336.
38. Migdalis I., Efthimiadis A., Pappas S., Alexopoulos D., Vlasserou F., Mikhailidis DP Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009 ; 25 (10). 2571-2576.
39. Fras Z., Mikhailidis DP Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin. 2008 ; 24 (9). 2467-2476.
40. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 ; 23 (8). 2009-2026.
41. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment of non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006 ; 22 (5). 873-883.
42. Ahmed MH, Byrne CD Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2009 ; 11 (3). 188-195.
43. Kaser S., Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract. 2010 ; 64 (7). 968-983.
44. Hatzitolios A., Savopoulos C., Lazaraki G., et al. Efficacy of omega-3 fatty acids atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004 ; 23 (4). 131-134.
45. Wiesinger HA, Shah J., White A., et al. Liver biochemistry abnormalities in a quaternary care lipid clinical database. Ann Hepatol. 2008 ; 7 (1). 63-66.
46. Ekstedt M., Franzen LE, Mathiesen UL, Holmqvist M., Bodemar G., Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007 ; 47 (1). 135-141.
47. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP Statins for non-alcoholic fatty liver disease: a new indication ? Aliment Pharmacol Ther. 2006 ; 24 (4). 698-699.
48. Schnell MA, Hardy C., Hawley M., Propert KJ, Wilson JM Effect of blood collection technique in mice on clinical pathology parameters. Hum Gene Ther. 2002 ; 13 (1). 155-161.
49. Hagedorn J., Arora R. Association of statins and diabetes mellitus. Am J Ther. 2010 ; 17 (2). e52 - e56.
50. Gao S., He L., Ding Y., Liu G. Mechanisms underlying different responses of plasma triglyceride to high-fat diets in hamsters and mice: role of hepatic MTP and triglyceride secretion. Biochem Biophys Res Commun. 2010 ; 398 (4). 619-626.